4E4 Stock Chart & Stats
€0.30
€2.84(70.70%)
At close: 4:00 PM EST
€0.30
€2.84(70.70%)
Day’s Range― - ―
52-Week Range€0.02 - €1.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€13.19M
Enterprise Value-€3.53B
Total Cash (Recent Filing)€3.54B
Total Debt (Recent Filing)€10.00M
Price to Earnings (P/E)―
Beta-2.90
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,630,814
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.12
Price to Sales (P/S)181.35
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.31Price Target Upside337.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthVery low leverage materially reduces near-term solvency risk and gives the company more optionality to finance commercialization or development milestones without immediate forced deleveraging. Over the next 2–6 months a light debt burden supports negotiation flexibility with partners and lenders and cushions operational volatility while executing go-to-market plans.
High Gross Margin & Revenue UptickAn extreme TTM revenue increase coupled with very high gross margins suggests product-level pricing power or favorable unit economics. If the company sustains demand and controls operating expenses, these structural revenue and margin characteristics improve the pathway to durable profitability and make commercialization investments more effective over the medium term.
Secured Near-Term Liquidity For CommercializationThe $11.4M structured financing extends runway to fund commercialization and product development, reducing immediate solvency pressures. Over the coming months this liquidity can enable key commercial launches, regulatory work, or partner engagements that are prerequisites for longer-term revenue conversion and de-risking of the business model.
Bears Say
Persistent Cash BurnMaterial negative operating and free cash flow indicate the business is consuming capital rather than self-funding. Persisting cash burn forces reliance on external financing, which can dilute shareholders or impose restrictive terms, and constrains reinvestment into commercialization or R&D, raising execution risk over the medium term.
Deep, Sustained LossesHeavily negative net margins and large operating losses mean current operations do not generate returns on invested capital. This structural unprofitability weakens the firm's ability to self-finance growth, undermines return on equity, and lengthens the time and execution required to reach sustainable profitability absent material improvements to cost structure or revenue scale.
Restrictive Financing Covenants & Trigger RisksThe secured promissory notes include broad collateral claims, strict covenants and Major/Minor Trigger Events that can raise balances by up to 25% or accelerate repayment. These structural constraints reduce strategic flexibility, increase refinancing risk, and could force costly deleveraging or curtailed investment if covenant thresholds are breached in a stressed operating period.
Scienture Holdings News
4E4 FAQ
What was Scienture Holdings, Inc.’s price range in the past 12 months?
Scienture Holdings, Inc. lowest stock price was €0.02 and its highest was €1.90 in the past 12 months.
What is Scienture Holdings, Inc.’s market cap?
Scienture Holdings, Inc.’s market cap is €13.19M.
When is Scienture Holdings, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Scienture Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is Scienture Holdings, Inc. overvalued?
According to Wall Street analysts Scienture Holdings, Inc.’s price is currently Undervalued.
Does Scienture Holdings, Inc. pay dividends?
Scienture Holdings, Inc. does not currently pay dividends.
What is Scienture Holdings, Inc.’s EPS estimate?
Scienture Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scienture Holdings, Inc. have?
Scienture Holdings, Inc. has 40,630,814 shares outstanding.
What happened to Scienture Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scienture Holdings, Inc.?
Currently, no hedge funds are holding shares in DE:4E4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scienture Holdings, Inc.
As a health services IT enterprise, TRxADE HEALTH, Inc. manages an online platform designed to facilitate transactions between licensed pharmaceutical wholesalers and healthcare providers. This digital marketplace enables wholesalers to distribute a broad spectrum of products and services, encompassing branded and generic drugs as well as other non-pharmaceutical items. Customers for these offerings span government organizations, hospitals, medical clinics, and independent pharmacies. The firm's corporate base is situated in Tampa, Florida.
4E4 Stock 12 Month Forecast
Average Price Target
€1.31
▲(337.05% Upside)